.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Chubb
Novartis
Deloitte
Express Scripts
Argus Health
Fuji
Fish and Richardson
Farmers Insurance

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,956,030

« Back to Dashboard

Details for Patent: 6,956,030

Title: Use of mometasone furoate for treating upper airway diseases
Abstract:The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
Inventor(s): Sequeira; Joel A. (Scotch Plains, NJ), Cuss; Francis M. (Basking Ridge, NJ), Nolop; Keith B. (Millburn, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Nagabhushan; Nagamani (Parsippany, NJ), Patrick; James E. (Belle Meade, NJ), Cayen; Mitchell (Bedminster, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Filing Date:Jan 22, 2004
Application Number:10/763,143
Claims:1. A method of treating a corticosteroid-responsive disease of the upper airway passages comprising administering once daily to nasal passages about 400 micrograms of mometasone furoate.

2. The method of claim 1, wherein the mometasone furoate is administered as anhydrous mometasone furoate.

3. The method of claim 1, wherein the mometasone furoate is administered as memetasone furoate monohydrate.

4. The method of claim 1, wherein the mometasone furoate is administered in the form of an aqueous suspension.

5. The method of claim 1, wherein the mometasone furoate is administered in the form of an aqueous suspension of mometasone furoate monohydrate.

6. The method of claim 1, wherein the mometasone furoate is administered in the form of an aqueous suspension of anhydrous mometasone furoate.

7. The method of claim 1, wherein there are administered 400 micrograms of mometasone furoate by applying four times to each nostril about 50 micrograms of mometasone furoate.

8. A method of treating a corticosteroid-responsive disease, comprising administering once daily to nasal passages an aqueous nasal spray comprising mometasone furoate monohydrate, in an amount providing about 200 micrograms of mometasone furoate to each nostril.

9. The method of claim 8, wherein there are administered 400 micrograms of mometasone furoate by applying four times to each nostril about 50 micrograms of mometasone furoate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Colorcon
Argus Health
Fish and Richardson
QuintilesIMS
US Department of Justice
Chinese Patent Office
Healthtrust
Accenture
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot